DERM News and Press, Journey Medical Corporation From 08/12/23

2023-08-12 10:15:17 ET Journey Medical Corporation (DERM) Q2 2023 Earnings Conference Call August 8 2023 4:00 PM ET Company Participants Matt Blazei - CoreIR Claude Maraoui - Co-Founder, President and Chief Executive Officer Joseph Benesch - Interim Chief Financi...

2023-08-08 17:30:40 ET Journey Medical press release ( NASDAQ: DERM ): Q2 GAAP EPS of -$0.46 misses by $0.12 . Revenue of $17.2M (-6.0% Y/Y) beats by $2.39M . For further details see: Journey Medical GAAP EPS of -$0.46 misses by $0.12, revenue of $17.2M b...

The Company generated total net revenues of $17.2 million in the second quarter of 2023, a 41% increase from $12.2 million in the first quarter of 2023 Announced positive topline results from two Phase 3 clinical trials evaluating DFD-29 (minocycline hydrochloride modified release capsu...

Company to host conference call to discuss financial results and provide a corporate update on August 8, 2023 at 4:30 p.m. ET Company and Neal Bhatia, MD, Director of Clinical Dermatology, Therapeutics Clinical Research, San Diego, CA and Investigator in over 75 clinical trials includin...

2023-08-01 05:25:31 ET Summary B. Riley Financial's recent equity raise suggests one of two scenarios, an acknowledgment of untenable dividend policy, or an effort to recalibrate its financial leverage, restoring balance to its sheets. Despite marketing its diversification strateg...

SCOTTSDALE, Ariz., July 19, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutic...

2023-07-11 13:19:00 ET Gainers: Eloxx Pharmaceuticals ( ELOX ) +112% . CytoMed Therapeutics Limited ( GDTC ) +102% . Biodexa Pharmaceuticals ( BDRX ) +92% . SOS Limited ( SOS ) +39% . Freeline Therapeutics Holdings ( FRLN ) +33% ...

2023-07-11 10:06:43 ET Gainers: CytoMed Therapeutics ( GDTC ) +128% . Eloxx Pharmaceuticals ( ELOX ) +29% . UpHealth ( UPH ) +13% . Virios Therapeutics ( VIRI ) +13% . Acumen Pharmaceuticals ( ABOS ) +9% . Losers: Jou...

The Phase 3 clinical trials achieved the co-primary and all secondary endpoints and subjects completed the 16-week treatment with no significant safety issues DFD-29 demonstrated statistical superiority over both Oracea ® (doxycycline) capsules and placebo for IGA treat...

2023-07-11 08:20:47 ET Viridian Therapeutics VRDN -19% following thyroid eye disease asset data . ADC Therapeutics ( ADCT ) -16% announces voluntary pause of enrollment in the Phase 2 LOTIS-9 Clinical Trial of ZYNLONTA and Rituximab in unfit or frail previously untre...